The Response to Illicit Drugs Act creates two parallel legal tools: (1) a statutory tort for persons who commit an “illicit drug‑related wrong” that causes disease, injury or death, and (2) an independent, direct right for the Saskatchewan government to sue to recover the province’s health and related costs arising from those wrongs, either for identified individuals or on an aggregate, population basis.
The Act also inserts sweeping administrative controls: it deems appointments, grants and government agreements to include terms allowing the Crown to void them if the recipient is convicted of specified Schedule I offences (including a three‑year lookback), extinguishes legal claims arising from such voidings, and shields government actors acting under the statute from suit. The combination of aggregate recovery, population‑level evidence rules, and broad regulatory and immunity powers makes implementation legally and operationally consequential for public agencies, health data custodians, and anyone who contracts or receives funding from the Crown.
At a Glance
What It Does
The bill creates a statutory tort for illicit drug‑related harms and a separate, direct cause of action for the Government to recover the present value of government expenditures tied to those harms. It permits aggregate suits where the province need not identify individual victims and establishes rebuttable presumptions to support population‑level causation and quantum.
Who It Affects
Provincial government entities, health authorities and data custodians, recipients of government appointments, grants or contracts (including Crown corporations), individuals and corporations involved in trafficking/production of Schedule I substances, and courts managing complex aggregate proof and discovery issues.
Why It Matters
It shifts how causation and damages can be proven in drug‑related civil litigation by authorizing epidemiological and sampling evidence and by lowering proof burdens in aggregate claims. It also creates a broad administrative mechanism for the Crown to terminate relationships and extinguish related legal claims, centralizing discretion in the executive and potentially changing incentives for fund recipients and suppliers in the illicit‑drug supply chain.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act does three major things in substance. First, it creates a new tort: if a person commits an offence under specified provisions of the federal Controlled Drugs and Substances Act in relation to a Schedule I drug and an individual’s use or exposure to that drug causes disease, injury or death, that person can be sued in Saskatchewan civil court for damages.
The Act creates a rebuttable presumption in favour of plaintiffs and authorizes damages including punitive awards and orders to account for and recover any profit the defendant earned from the wrongful conduct.
Second, the province itself gains a standalone cause of action to recover the ‘illicit drug‑related costs’ it has incurred or reasonably expects to incur. The measure expressly allows the Government to pursue recovery either for specific insured individuals or, crucially, on an aggregate basis for a defined population.
For aggregate suits the Government need not identify victims or prove causation and costs at the individual level; instead the statute provides rebuttable presumptions and permits the use of population‑based evidence such as epidemiological studies and sampling.Third, the Act alters the Crown’s contractual and administrative relationships: appointments, grants and agreements with the Crown are statutorily deemed to include terms making them voidable if the appointee, grantee or contractee has a qualifying Schedule I conviction (including convictions within three years prior to appointment/grant/agreement). If the Crown exercises that discretion, legal claims arising from the termination are extinguished and the Crown is insulated from related suits.
The Act gives the Lieutenant Governor in Council wide regulation‑making authority to define health care benefits, prescribe costs, exempt classes of persons, and otherwise fill gaps necessary for operation.Those changes interact: aggregate recovery leans on population evidence and limited discovery (the statute limits production of individual health records except for court‑ordered statistically meaningful samples with identifiers removed), while immunity and extinguishment provisions limit counterclaims against the Crown. Together, the provisions reallocate litigation strategy away from conventional person‑by‑person tort proof toward epidemiological proof, ministerial discretion and regulatory implementation choices that will determine the practical reach of the law.
The Five Things You Need to Know
The Government gets a direct statutory right to sue for the present value of ‘illicit drug‑related costs’—including health benefits, coroner and residential services costs—either for named individuals or on an aggregate, population basis.
Aggregate actions rely on statutory rebuttable presumptions of causation and exposure and do not require identification of particular victims or individual proof of medical causation.
Appointments, grants and agreements with the Crown are deemed to include terms allowing the Crown to void or terminate them if the recipient has a Schedule I conviction, including convictions within the three years before the appointment, and such voiding extinguishes claims for loss or damage (except pension entitlements).
Section 12 makes population‑based epidemiological and sampling evidence admissible to establish causation and quantum, and it shields good‑faith information providers to the Government from civil actions for supplying that evidence.
The statute authorizes courts to order accounting for profits and to apportion liability among multiple defendants based on each party’s contribution to the risk of harm, with enumerated factors (time, toxicity, concerted action) guiding apportionment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions and scope
Part 1 supplies the operative definitions used throughout: crucially it defines ‘illicit drug’ by reference to Schedule I of the federal Controlled Drugs and Substances Act, and it defines ‘illicit drug‑related costs’ to include present‑value calculations of government health and related expenditures. Those definitions lock the Act’s reach to federal Schedule I substances and tie recovery to prescribed categories of public spending — a mechanistic choice that will frame later regulation‑making about what counts as a recoverable cost.
Automatic contract terms, termination power, and extinguishment
This Part deems every Crown appointment, grant or agreement to include a term letting the government void or refuse the relationship if the recipient has a qualifying Schedule I conviction, including a three‑year lookback window. It excludes some employees (notably those covered by collective agreements) only as prescribed. The Part goes further: it extinguishes any claims for loss or damage arising from that enactment or application and bars litigation against the Crown and its agents. Practically, that converts ministerial decisions about eligibility into near‑unreviewable rights to terminate relationships without severance (except pension entitlements) and forecloses contractual and tort remedies for those affected.
Province’s standalone recovery claim and aggregate suits
Part 3 grants Saskatchewan an independent cause of action to recover illicit drug‑related costs and allows the Government to pursue aggregate recovery for populations exposed to an illicit drug. For aggregate suits the Government must prove on a balance of probabilities that the defendant committed the illicit‑drug wrong, that use or exposure to the drug can cause the asserted harms, and that the defendant trafficked, produced, imported or exported some portion of the drug in Saskatchewan. If those thresholds are met, statutory presumptions can shift causation and quantum to the Government, though defendants can rebut by proving lack of causation. The Part also limits disclosure of individual health records while permitting courts to order discovery of statistically meaningful samples with identifiers redacted.
New private cause of action and remedies
Part 4 creates a private cause of action for individuals harmed by illicit‑drug wrongs, including a statutory rebuttable presumption that exposure and harm were caused by the illicit‑drug wrong. Remedies include all conventional damage heads plus orders accounting for profits and other equitable relief; the section clarifies that this statutory tort supplements existing common‑law and statutory remedies rather than replacing them. The interaction with The Health Administration Act is limited: plaintiffs cannot recover health‑service costs from the Minister under subsection 19(5) of that Act within these claims.
Population evidence, risk‑contribution liability, immunities and broad regulatory power
Section 12 expressly admits statistical and epidemiological evidence (including sampling) for causation and damages, and protects good‑faith information suppliers to the Government from suits. Section 13 allows liability to be apportioned among multiple defendants based on each party’s contribution to the risk of harm where direct causation can’t be pinned on one actor, listing factors the court may use (duration, toxicity, concerted action). Section 14 grants broad immunity to government actors acting under the Act, and section 15 gives the Lieutenant Governor in Council sweeping regulation‑making authority to define health benefits, prescribe costs, carve out exemptions, and align other statutes with this Act.
Commencement
The Act does not have an automatic commencement date: it comes into force by order of the Lieutenant Governor in Council, meaning the Crown controls the timing and can stage implementation, including regulatory prerequisites and operational readiness for aggregate litigation.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Saskatchewan Government and Treasury — gains a direct, statutory recovery tool to recoup present‑value health and related costs tied to illicit‑drug wrongs, potentially reducing net taxpayer burden from illicit‑drug expenditures.
- Taxpayers in Saskatchewan — if recovery actions are successful, the province may offset public health and coroner costs that would otherwise be borne by taxpayers, shifting the financial burden onto liable defendants and their assets.
- Private plaintiffs harmed by illicit drugs — the statutory tort creates a rebuttable presumption of causation, expands available remedies (including punitive damages and profit disgorgement), and permits use of population‑level evidence to support individual claims.
- Public health authorities and researchers — the Act expressly admits epidemiological and sampling evidence, elevating the evidentiary value of population health studies for litigation and policymaking.
- Government contractors and grant recipients in certain sectors — the Executive Council’s ability to add illicit‑drug‑related terms can protect recipients that proactively comply or adopt risk‑mitigation measures, by allowing tailored conditions that limit future Crown exercise of termination powers.
Who Bears the Cost
- Individuals and entities involved in trafficking, producing, importing or exporting Schedule I substances — the statute targets those actors for civil liability, disgorgement of profits, and proportionate allocation of aggregate costs.
- Grant and contract recipients, and non‑union public officers — appointments, grants and agreements are now exposed to ministerial voiding if a qualifying conviction exists, and related claims are statutorily extinguished, creating financial and reputational risk for recipients.
- Health data custodians and public authorities — courts may order production of statistically meaningful samples and regulators will likely require new reporting; these obligations create administrative costs and complex privacy compliance questions.
- Courts and judicial administrators — aggregate claims, population evidence and novel apportionment rules will increase litigation complexity, requiring additional judicial time, expert management and possibly new procedural rules.
- Small organizations and advocacy groups — groups receiving government funding could face abrupt termination and a loss of remedies if a member or employee has a past qualifying conviction, even when that person’s role is unrelated to the funded activity.
Key Issues
The Core Tension
The Act trades conventional individualised fault‑based tort proof and contractual remedies for centralized executive discretion and population‑level proof: it seeks to make the Crown whole by aggregating harms and relying on epidemiological methods, but doing so compresses individualized due process, intensifies data‑privacy conflicts, and shifts burden onto courts and non‑state defendants to resolve technical, scientific and policy disputes that traditionally split between public health and civil litigation.
The Act creates practical and doctrinal tensions that implementation will force to the surface. First, aggregate recovery and population‑level presumptions ease proof for plaintiffs and the Crown but place heavy reliance on epidemiological methods and sampling design; courts will have to translate public‑health measures (exposure prevalence, attributable fractions, confidence intervals) into civil‑law standards of causation and quantum.
Determining the present value of future government expenditures at a population level also demands contested actuarial assumptions and choices about discount rates, counterfactual scenarios, and which categories of public spending are ‘reasonably expected’ to arise.
Second, the scheme limits discovery of individual health records yet permits disclosure of statistically meaningful samples with identifiers removed. That raises privacy, data stewardship and evidentiary chain‑of‑custody questions: who selects the sample, what redaction standard protects confidentiality while preserving probative value, and how will courts resolve disputes over de‑identification and re‑identification risk?
The Act’s immunity and extinguishment clauses further complicate accountability pathways by removing some avenues for redress against the Crown, which will concentrate dispute resolution in private suits against non‑state actors and in judicial review challenges to executive discretion.
Third, the Act vests broad delegated powers in the Lieutenant Governor in Council to define health benefits, prescribe costs, exempt classes and even suspend the application of other Acts. That creates implementation risk: administratively‑driven definitions and carve‑outs could materially expand or shrink the law’s reach, and those regulatory choices will be decisive—but also politically and legally contestable—steps in applying the statute.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.